CERVIMAX™ IHC
The CERVIMAX™ IHC monoclonal antibody kit shows outstanding immunoreactivity for the detection of E7 antigen in paraffin-embedded tissues.
Features of the Cervimax IHC kit
- Reliable detection of E7 protein expression in paraffin-embedded tissues or paraformaldehyde-immobilized cells by immunohistochemical staining.
- Detection of high-risk E7 oncogenic proteins of the Alpha-Papillomavirus genus, species 5, 6, 7 and 9.*
- Ready-to-use kit. Compatible with major immunohistochemical staining systems.
- Superior sensitivity: high signal to noise ratio.
- Standardized kit with clear read-out structure.
- Ease of use: a highly optimized procedure detailing each step of the process.
- Less than 4-hour turnover from sampling to result: well suited to routine testing.
- Extensive in-house studies show consistently reliable performance on a wide range of tissue samples.
Targeted E7 Detection
Since E7 was identified as the primary oncogene in cervical cancer, the lack of robust functional monoclonal antibodies has proven to be a major obstacle in HPV research.
The difficulty in detecting E7 proteins in clinical samples was commonly attributed to the low abundance and high instability of E7 proteins. However, the CERVIMAX™ IHC system shows that E7 is a robust and highly abundant antigen in clinical cervical cancer samples prepared under standardized protocols.
With the CERVIMAX™ IHC kit, E7 proteins can be detected from fresh IHC samples and also from properly conserved historical paraffin-embedded samples that are more than 30 years old. Our extensive in-house studies show consistently reliable performance on a wide range of tissue samples.
The CERVIMAX™ IHC kit contains a mixture of highly purified monoclonal antibodies against high-risk E7 proteins which exhibit sufficient epidemiological evidence for malignant transforming activity in humans. These monoclonal antibodies have been carefully selected and optimized for use in immunohistochemistry (IHC).
